Last reviewed · How we verify

Port-sites infiltration:Bupivacaine0.25%

Hospital General Universitario Elche · Phase 3 active Small molecule

Port-sites infiltration:Bupivacaine0.25% is a Local anesthetic Small molecule drug developed by Hospital General Universitario Elche. It is currently in Phase 3 development for Postoperative pain management, Regional anesthesia. Also known as: Port-sites infiltration with bupivacaine.

Bupivacaine blocks sodium channels in nerve fibers, preventing depolarization and relieving pain.

Bupivacaine 0.25% port-sites infiltration is used for postoperative analgesia in laparoscopic sleeve gastrectomy. It has completed a Phase 3 trial and shows promise in reducing pain without significant safety concerns.

At a glance

Generic namePort-sites infiltration:Bupivacaine0.25%
Also known asPort-sites infiltration with bupivacaine
SponsorHospital General Universitario Elche
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Bupivacaine acts as a local anesthetic by inhibiting the influx of sodium ions through voltage-gated sodium channels, which are essential for the initiation and propagation of nerve impulses. This blockade of sodium channels prevents the depolarization of nerve fibers, resulting in a loss of sensation and pain relief.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Port-sites infiltration:Bupivacaine0.25%

What is Port-sites infiltration:Bupivacaine0.25%?

Port-sites infiltration:Bupivacaine0.25% is a Local anesthetic drug developed by Hospital General Universitario Elche, indicated for Postoperative pain management, Regional anesthesia.

How does Port-sites infiltration:Bupivacaine0.25% work?

Bupivacaine blocks sodium channels in nerve fibers, preventing depolarization and relieving pain.

What is Port-sites infiltration:Bupivacaine0.25% used for?

Port-sites infiltration:Bupivacaine0.25% is indicated for Postoperative pain management, Regional anesthesia.

Who makes Port-sites infiltration:Bupivacaine0.25%?

Port-sites infiltration:Bupivacaine0.25% is developed by Hospital General Universitario Elche (see full Hospital General Universitario Elche pipeline at /company/hospital-general-universitario-elche).

Is Port-sites infiltration:Bupivacaine0.25% also known as anything else?

Port-sites infiltration:Bupivacaine0.25% is also known as Port-sites infiltration with bupivacaine.

What drug class is Port-sites infiltration:Bupivacaine0.25% in?

Port-sites infiltration:Bupivacaine0.25% belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is Port-sites infiltration:Bupivacaine0.25% in?

Port-sites infiltration:Bupivacaine0.25% is in Phase 3.

What are the side effects of Port-sites infiltration:Bupivacaine0.25%?

Common side effects of Port-sites infiltration:Bupivacaine0.25% include Central nervous system toxicity, Cardiovascular toxicity, Nausea and vomiting.

What does Port-sites infiltration:Bupivacaine0.25% target?

Port-sites infiltration:Bupivacaine0.25% targets Voltage-gated sodium channels and is a Local anesthetic.

Related